Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MediStem Inc.
Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.
This week’s announcements include Valeant’s appointment of an executive vice president finance, Editas Medicine’s appointment of a chief scientific officer, Clintec’s appointment of AstraZeneca’s former global research director and various board appointments by Acadia, Scancell, PhaseRx and Gilead.
Batu Biologics, a San Diego biotechnology company developing cancer angiogenesis-targeting immunotherapeutic product ValloVax, has named Dr Alan Lewis as chair of its board of directors. Dr Lewis has previously been vice-president of research at Wyeth-Ayerst, and CEO at Signal Pharmaceuticals, Novocell, and the Juvenile Diabetes Research Foundation. Most recently he was CEO of Medistem, where he worked with Batu Biologics co-founder Dr Thomas Ichim.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2013 through January 2014.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.